Biomarin Pharmaceutical Inc. (BMRN) revealed earnings for first quarter that declined from the same period last year.
The company's earnings came in at $17.37 million, or $0.09 per share. This compares with $81.38 million, or $0.44 per share, in last year's first quarter.
Analysts had expected the company to earn -$0.10 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter fell 3.2% to $486.03 million from $502.07 million last year.
Biomarin Pharmaceutical Inc. earnings at a glance:
-Earnings (Q1): $17.37 Mln. vs. $81.38 Mln. last year.-EPS (Q1): $0.09 vs. $0.44 last year.-Analysts Estimate: -$0.10-Revenue (Q1): $486.03 Mln vs. $502.07 Mln last year.
-Guidance:Full year revenue guidance: $1,750 - $1,850 Mln
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.